Gold Falls Below $4,000 as Strong Dollar and Fed Rate Hike Expectations Weigh on Prices 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Wall Street Ends Mixed as Micron Surges, Apple Drops After Price Hikes 
Johns Hopkins University Lays Off 110 Employees as Federal Research Funding Declines 
Oil Prices Drop as Strait of Hormuz Shipping Recovers 
NASA and Roscosmos Chiefs Meet in Florida to Discuss Moon and ISS Cooperation 
SpaceX Eyes Starlink Mobile Phone Service to Challenge Verizon, AT&T, and T-Mobile 
SpaceX’s Starship Completes 11th Test Flight, Paving Way for Moon and Mars Missions 
SK Hynix Targets $29.4 Billion Nasdaq Listing to Expand AI Chip Business 
Supreme Court Blocks 5th Circuit Ruling on Abortion Pill Access 
Gold Prices Fall Below $4,000 as Strong Dollar, Fed Rate Hike Bets Weigh on Bullion 
Wall Street Ends Lower as AI Stocks Drag Markets, Fed Rate Outlook Shifts 
Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
Trump Administration to Launch Autism Initiatives Targeting Acetaminophen Use and New Treatment Options 
Novo Nordisk Raises 2026 Outlook on Strong Wegovy Demand 
RFK Jr. Spokesman Resigns Over Trump Administration’s Flavored E-Cigarette Policy 
South Korea will invest 274.6 billion won in the bio-industry this year for 252 new R&D projects in the four fields of biopharmaceuticals, healthcare, biomaterials, and medical equipment in 2023.
According to South Korea’s Ministry of Trade, Industry and Energy, 94.8 billion won would be allocated to developing new medicines, microbiome analysis, and other biomanufacturing process technology.
Around 69.5 billion won will support the development of advanced medical appliances, and 30 billion won will be for developing state-of-the-art biomaterials.
The ministry added that beefing up support for biomaterials and other new fields of the sector would promote innovation.
